Neoleukin Therapeutics (NLTX) Competitors $23.47 +0.38 (+1.65%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. MGTX, OLMA, ANAB, KROS, SIGA, GOSS, ARVN, KALV, SVRA, and ETONShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include MeiraGTx (MGTX), Olema Pharmaceuticals (OLMA), AnaptysBio (ANAB), Keros Therapeutics (KROS), Siga Technologies (SIGA), Gossamer Bio (GOSS), Arvinas (ARVN), KalVista Pharmaceuticals (KALV), Savara (SVRA), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Its Competitors MeiraGTx Olema Pharmaceuticals AnaptysBio Keros Therapeutics Siga Technologies Gossamer Bio Arvinas KalVista Pharmaceuticals Savara Eton Pharmaceuticals Neoleukin Therapeutics (NASDAQ:NLTX) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Do analysts recommend NLTX or MGTX? MeiraGTx has a consensus price target of $24.00, indicating a potential upside of 190.56%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MeiraGTx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility & risk, NLTX or MGTX? Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Is NLTX or MGTX more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -415.39%. Neoleukin Therapeutics' return on equity of -37.22% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% MeiraGTx -415.39%-314.44%-63.28% Which has preferable valuation & earnings, NLTX or MGTX? Neoleukin Therapeutics has higher earnings, but lower revenue than MeiraGTx. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.55MeiraGTx$33.28M19.97-$147.79M-$2.04-4.05 Do institutionals and insiders believe in NLTX or MGTX? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 7.5% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer NLTX or MGTX? In the previous week, MeiraGTx had 4 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for MeiraGTx and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat MeiraGTx's score of -0.04 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neoleukin Therapeutics Neutral MeiraGTx Neutral SummaryMeiraGTx beats Neoleukin Therapeutics on 10 of the 15 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$220.57M$1.05B$6.11B$10.56BDividend YieldN/A4.84%5.69%4.75%P/E Ratio-7.551.2685.4827.60Price / SalesN/A28.98616.90236.99Price / CashN/A17.6437.9261.55Price / Book2.127.5213.136.76Net Income-$57.56M-$7.77M$3.30B$275.88M7 Day Performance30.57%26.65%4.29%2.81%1 Month Performance20.67%27.90%9.45%9.24%1 Year Performance-52.63%-5.67%86.64%35.42% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$23.47+1.6%N/A-53.4%$220.57MN/A-7.5590High Trading VolumeMGTXMeiraGTx4.0582 of 5 stars$8.23-0.2%$24.00+191.6%+99.0%$663.69M$33.28M-4.03300News CoveragePositive NewsAnalyst ForecastInsider TradeGap UpOLMAOlema Pharmaceuticals2.6649 of 5 stars$9.79+2.6%$24.00+145.1%-5.9%$654.77MN/A-4.9470News CoverageAnalyst ForecastANABAnaptysBio2.5084 of 5 stars$30.62+31.6%$48.75+59.2%-1.6%$651.49M$123.16M-6.83100Analyst ForecastGap UpHigh Trading VolumeKROSKeros Therapeutics2.8317 of 5 stars$15.82-0.8%$30.00+89.6%-73.3%$647.82M$3.55M51.03100Analyst ForecastSIGASiga Technologies2.0896 of 5 stars$9.15+2.1%N/A+24.1%$641.59M$138.72M8.1040News CoveragePositive NewsAnalyst ForecastGOSSGossamer Bio3.9064 of 5 stars$2.63-6.7%$8.50+223.2%+137.3%$641.21M$114.70M-4.24180Analyst ForecastARVNArvinas2.9988 of 5 stars$8.52-0.1%$16.18+90.0%-62.2%$626.25M$263.40M-8.44420Analyst ForecastKALVKalVista Pharmaceuticals3.8263 of 5 stars$12.18-0.2%$26.43+117.0%+2.5%$616.89M$1.43M-3.09100Analyst ForecastSVRASavara2.7173 of 5 stars$3.57+1.4%$7.50+110.1%-8.2%$608.39MN/A-7.1420Trending NewsAnalyst ForecastETONEton Pharmaceuticals1.8664 of 5 stars$21.73-3.3%$29.67+36.5%+182.8%$602.86M$39.01M-135.8120Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies MeiraGTx Alternatives Olema Pharmaceuticals Alternatives AnaptysBio Alternatives Keros Therapeutics Alternatives Siga Technologies Alternatives Gossamer Bio Alternatives Arvinas Alternatives KalVista Pharmaceuticals Alternatives Savara Alternatives Eton Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
